Increasing breast cancer cases and growing health care spend have opened up the breast cancer drug market. Developing countries such as Brazil, India and China in particular have been emerging as potential markets.
London, UK, November 25, 2010 — Various players have been making strategic acquisitions to explore new markets and strengthen R&D.
Over the years, patient spend on healthcare has fallen. This is mainly due to several medical assistance programs introduced by governments across countries. Moreover insurance companies have started covering a wide range of cancer treatments. Both these trends are driving the sales of breast cancer drugs.
TechNavio’s analyst says, “Breast cancer is the second most common form of cancer. This spells huge potential for breast cancer drug makers across global markets. The North and Latin American markets alone accounted for $4,549.4 million in 2009.”
According to TechNavio, the market for Global Breast Cancer Drugs is forecast to reach $12,548.3 million in 2013 from $8,600.0 million in 2009 at a CAGR of 9.9 percent.
TechNavio has published a report on this subject titled “Global Breast Cancer Drugs Market 2009-2013”. This report has been prepared based on a study of the global breast cancer drugs market with a focus on regional trends. Inputs from industry experts, vendors and end-users were used in the analysis. The report includes a market size estimate and forecast, market landscape, vendor landscape, drivers, challenges and trends in this market.
For further information visit http://www.technavio.com/content/global-breast-cancer-drugs-market-2009-2013
Press Release Distribution By PressReleasePoint
Contact:
Ludmila Berkesova
Infiniti Research Limited
Third Floor
33 Cavendish Square
London W1G 0PW
United Kingdom
0044 207 031 0969
[email protected]
http://www.technavio.com
